AlloVir is a biopharmaceutical company focused on developing allogeneic T-cell therapies to combat viral diseases. Its proprietary virus-specific T cell (VST) therapy platform enables the creation of off-the-shelf VSTs, designed to restore immunity in patients with T cell deficiencies at risk from life-threatening viral infections.
Kalaris Therapeutics is a clinical-stage biopharmaceutical business committed to researching and commercializing medicines for common retinal illnesses.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.